Comparing mpMRI and TURBT for diagnosing muscle-invasive bladder cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study aims to validate the accuracy of the VI-RADS score obtained through multi-parametric magnetic resonance imaging (mpMRI) against the pathologic cancer stage determined by diagnostic transurethral bladder tumor resection (TURBT). It will also evaluate the clinical and quality of life outcomes associated with these two diagnostic methods in patients suspected of having muscle-invasive bladder cancer (MIBC). The study will enroll participants who meet specific eligibility criteria and will involve both imaging and surgical procedures to gather comprehensive data.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 years old or greater at the time of consent.
* Suspected muscle-invasive bladder cancer by tumor appearance on initial routine cystoscopy as determined by the UCI-affiliated provider performing this procedure.
* ECOG Performance Status of 0-3.
* Patients must have the ability to understand and the willingness to sign a written informed consent document (prior to the initiation of the study and any study procedures).
* Patients must be willing and able to comply with the scheduled visits, imaging plan, follow up plan, and other specified study procedures in the opinion of the Investigator.

Exclusion Criteria:

* Prior TURBT within 120 days of study entry.
* Prior therapy for bladder cancer within 180 days of study entry.
* Inability to tolerate mpMRI or associated contrast.
* Inability to tolerate TURBT or associated anesthesia.
* ECOG Performance Status of 4.
* Female patient who is known to be pregnant or breastfeeding.

Where it's running

• Chao Family Comprehensive Cancer Center University of California, Irvine
  Orange, California, United States Recruiting

Study contacts

• Principal investigator: Nataliya Mar, MD — Chao Family Comprehensive Cancer Center
• Study coordinator: Chao Family Comprehensive Cancer Center University of California, Irvine
• Email: ucstudy@uci.edu
• Phone: 1-877-827-8839

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• FDG PET/CT for Muscle-Invasive Bladder Cancer: Baseline Staging and Chemotherapy Response

  This study tests how well 18F-FDG PET/CT can stage muscle-invasive bladder cancer and predict how patients respond to neoadjuvant chemotherapy.

  Recruiting University Hospital of Ferrara · Ferrara · NCT07750470

• Enfortumab vedotin plus pembrolizumab to help people with muscle-invasive bladder cancer keep their bladder

  This trial tests whether giving enfortumab vedotin together with pembrolizumab can let people with muscle-invasive bladder cancer avoid bladder removal.

  Recruiting at 68 sites Phase 2 Astellas Pharma Inc · Little Rock, Arkansas and 67 other locations · NCT07475806

• Collecting blood and leftover tumor tissue to test molecular residual disease (MRD) detection

  This project will test whether blood and leftover tumor tissue from adults with certain solid tumors can be used with Natera's MRD blood tests to find tiny amounts of cancer (ctDNA) after treatment.

  Recruiting Natera, Inc. · Austin, Texas · NCT07318051

• Pre-surgery chemotherapy and MRI accuracy for staging muscle-invasive bladder cancer

  This project will see if giving chemotherapy before surgery changes how accurately MRI can stage muscle-invasive bladder cancer in people scheduled for cystectomy.

  Recruiting Assiut University · Asyut, Asyut Governorate and 1 other locations · NCT07202819

• Combining rutin with immunotherapy and chemotherapy for bladder cancer treatment

  This study is testing if adding rutin to standard bladder cancer treatments can help patients whose cancer hasn't responded to chemotherapy feel better and improve their outcomes.

  Recruiting Phase 1 First Affiliated Hospital of Chongqing Medical University · Chongqing, Chongqing Municipality · NCT06916494

• Tetra-modality bladder-preservation approach in muscle-invasive bladder cancer

  This trial tests whether adding the immunotherapy drug avelumab to tumor removal, chemotherapy, and radiation can help people with muscle-invasive bladder cancer keep their bladder.

  Recruiting Phase 2 American University of Beirut Medical Center · Beirut, Beirut · NCT06686381

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.